I am a clinically active urologist, focusing on the detection and treatment of malignancies in the prostate and kidney, as well as treating general urological conditions. I have been practicing urology since 2007. I have achieved degrees in General Surgery and Urology at Danderyds Hospital, and was awarded Fellow of the European Board of Urology (FEBU) in 2015.
I defended my thesis "Predicting Prostate Cancer- on the use of biomarkers in Prostate Cancer Diagnostics" in January 2015. During 2015 I undertook postdoctoral studies at University of California, San Francisco under the guidance of associate professor M Cooperberg, professor J Witte and professor JC Chan.
Since 2016 I combine urological practice at Danderyds Hospital with postdoctoral research at Karolinska Institutet.
2016- Postdoc (Dpt Medical Epidemiology and Biostatistics, KI)
2015- Clinical Urologist (Danderyds Hospital)
2015 Fellow of the European Board of Urology (FEBU)
2015 Postdoc (University of California, San Francisco)
2015 Ph.D. (Dpt Clinical Sciences at Danderyds Hospital, KI)
2013 General Surgeon (Danderyds Hospital)
2007 M.D. (KI)
The over-arching aim of my research is to improve detection and treatment of prostate cancer. My current work emanates from different perspectives, resulting in several different projects.
An improved diagnostic chain for prostate cancer
We hypothesize that using improved blood-based testing and imaging techniques will improve detection of prostate cancer. In large studies, our research group have shown the value of several biomarkers including the novel blood-test STHLM3. I am responsible for the STHLM3MR-projects, where we aim to investigate the value of Magnetic Resonance Imaging (MRI) in prostate cancer detection. The STHLM3MR Phase 2 study is a large randomized study, exploring a combination of using the STHLM3 test and targeted biopsies using MRI/Fusion tehnique.
Traditional tools for prostate cancer detection
Several tools are already availiable to aid decisions in prostate cancer diagnostics, but evidence are often scarce. Using contemporary, high-quality data, we systematically explore the value of traditionally used markers of prostate cancer risk such as prostate volume, voiding symtoms, repeated blood-testing et cetera.
Current diagnostics of prostate cancer
Using the populationbased cohort STHLM0, our research group work are describing how detection of prostate cancer i currently being performed. For example, we describe current patterns of PSA-testing, use of prostate biopsies and frequency of biopsy-related complications.
Academic honours, awards and prizes
2017 Astellas Cutting Edge Award
2016 European Association of Urology (EAU) Annual Meeting - Best poster award
2014 StratCan International Postdoc award
2011 StratCan Ph.D. award
2011 Research Resident